Acorda hits Par with infringement claim

Acorda Therapeutics has sued rival Par Pharmaceutical accusing it of infringing patents related to multiple sclerosis (MS) treatment drug Ampyra (dalfampridine).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Lupin scores another win in kidney drug dispute

22 May 2026 A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.

Americas

Battle over inhaler shape ends badly for Boehringer

21 May 2026 European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.

Americas

Jones Day adds in-house biologics specialist to Boston office

20 May 2026 The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.

More features

Lupin scores another win in kidney drug dispute

Battle over inhaler shape ends badly for Boehringer

Chinese medtech company fined by UPC over injunction breaches

Healthcare leads sweeping AI partnership in Singapore

Jones Day adds in-house biologics specialist to Boston office

Kirkland & Ellis subject of alleged conflict in trade secrets clash

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

Orrick lands five-member M&A team in Paris

Acorda hits Par with infringement claim

More on this story

Editor's picks

Editor's picks

More features